Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

ADC Therapeutics Q1 Adj. EPS $(0.22) Beats $(0.40) Estimate, Sales $23.03M Beat $17.71M Estimate

Author: Benzinga Newsdesk | May 14, 2025 08:04am
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.40) by 45 percent. This is a 42.11 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $23.03 million which beat the analyst consensus estimate of $17.71 million by 30.05 percent. This is a 27.57 percent increase over sales of $18.05 million the same period last year.

Posted In: ADCT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist